Skip to search boxSkip to navigationSkip to main content

Epidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries

  • Brooks W. Morgan
    ,
  • Matthew R. Grigsby
    ,
  • Trishul Siddharthan
    ,
  • Muhammad Chowdhury
    ,
  • Adolfo Rubinstein
    ,
  • Laura Gutierrez
  • Johns Hopkins University School of Medicine
    ,
  • b
    ,
  • Instituto de Efectividad Clínica y Sanitaria (IECS)
    ,
  • Universidad Peruana Cayetano Heredia
    ,
  • Universidad Peruana Cayetano Heredia
    ,
  • Faculty of Health
Research Output: Contribution to journal Article Peer-review

Open access

Publication Information

Output type

Research Output: Contribution to journal Article Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 1598-1606 (9 pages)

Journal (Volume, Issue Number)

Journal of Allergy and Clinical Immunology (Volume 143, Issue 4)

Publication milestones

  • Published - 04/2019

Publication status

Published - 04/2019

ISSN

0091-6749

Publication IDs

  • Scopus: 85056397458
  • PubMed: 30291842

Abstract

Background: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) represents the confluence of bronchial airway hyperreactivity and chronic airflow limitation and has been described as leading to worse lung function and quality of life than found with either singular disease process. Objective: We aimed to describe the prevalence and risk factors for ACO among adults across 6 low- and middle-income countries (LMICs). Methods: We compiled cross-sectional data for 11,923 participants aged 35 to 92 years from 4 population-based studies in 12 settings. We defined COPD as postbronchodilator FEV 1 /forced vital capacity ratio below the lower limit of normal, asthma as wheeze or medication use in 12 months or self-reported physician diagnosis, and ACO as having both. Results: The prevalence of ACO was 3.8% (0% in rural Puno, Peru, to 7.8% in Matlab, Bangladesh). The odds of having ACO were higher with household exposure to biomass fuel smoke (odds ratio [OR], 1.48; 95% CI, 0.98-2.23), smoking tobacco (OR, 1.28 per 10 pack-years; 95% CI, 1.22-1.34), and having primary or less education (OR, 1.35; 95% CI, 1.07-1.70) as compared to nonobstructed nonasthma individuals. ACO was associated with severe obstruction (FEV 1 %, <50; 31.6% of ACO vs 10.9% of COPD alone) and severe spirometric deficits compared with participants with asthma (−1.61 z scores FEV 1 ; 95% CI, −1.48 to −1.75) or COPD alone (−0.94 z scores; 95% CI, −0.78 to −1.10). Conclusions: ACO may be as prevalent and more severe in LMICs than has been reported in high-income settings. Exposure to biomass fuel smoke may be an overlooked risk factor, and we favor diagnostic criteria for ACO that include environmental exposures common to LMICs.

Funding Details

The Pulmonary Risk in South America Study was sponsored and funded by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH) in the United States (contract no. 268200900029C ). The CRONICAS study was supported by the NHLBI (contract no. HHSN268200900033C ). The Lung Function in Nakaseke and Kampala study was supported in part by the Fogarty International Center (grant no. 5R25TW009340 ) and by a COPD Discovery Award from Johns Hopkins University . W.C. is supported in part by the NIH (grant no. UM1HL134590). T.S. was supported by a National Research Service Award through the National Institute of Environmental Health Sciences of the NIH (grant no. 1F32ES028577 ). A.R. was supported by the NIH Office of the Director , Fogarty International Center , and the NHLBI through the International Clinical Research Fellows Program at Vanderbilt University (grant no. R24 TW007988 ) and the American Relief and Recovery Act. Disclosure of potential conflict of interest: R. A. Wise reports grants and/or personal fees from AstraZeneca/Medimmune, Boehringer Ingelheim, Contrafect, GlaxoSmithKline, Pfizer, Pulmonx, Roche, Spiration, Sunovion, Teva, Pearl Therapeutics, Merck, and Bonti outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. The Pulmonary Risk in South America Study was sponsored and funded by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH) in the United States (contract no. 268200900029C). The CRONICAS study was supported by the NHLBI (contract no. HHSN268200900033C). The Lung Function in Nakaseke and Kampala study was supported in part by the Fogarty International Center (grant no. 5R25TW009340) and by a COPD Discovery Award from Johns Hopkins University. W.C. is supported in part by the NIH (grant no. UM1HL134590). T.S. was supported by a National Research Service Award through the National Institute of Environmental Health Sciences of the NIH (grant no. 1F32ES028577). A.R. was supported by the NIH Office of the Director, Fogarty International Center, and the NHLBI through the International Clinical Research Fellows Program at Vanderbilt University (grant no. R24 TW007988) and the American Relief and Recovery Act.Disclosure of potential conflict of interest: R. A. Wise reports grants and/or personal fees from AstraZeneca/Medimmune, Boehringer Ingelheim, Contrafect, GlaxoSmithKline, Pfizer, Pulmonx, Roche, Spiration, Sunovion, Teva, Pearl Therapeutics, Merck, and Bonti outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. The Pulmonary Risk in South America Study was sponsored and funded by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH) in the United States (contract no. 268200900029C). The CRONICAS study was supported by the NHLBI (contract no. HHSN268200900033C). The Lung Function in Nakaseke and Kampala study was supported in part by the Fogarty International Center (grant no. 5R25TW009340) and by a COPD Discovery Award from Johns Hopkins University. W.C. is supported in part by the NIH (grant no. UM1HL134590). T.S. was supported by a National Research Service Award through the National Institute of Environmental Health Sciences of the NIH (grant no. 1F32ES028577). A.R. was supported by the NIH Office of the Director, Fogarty International Center, and the NHLBI through the International Clinical Research Fellows Program at Vanderbilt University (grant no. R24 TW007988) and the American Relief and Recovery Act. Disclosure of potential conflict of interest: R. A. Wise reports grants and/or personal fees from AstraZeneca/Medimmune, Boehringer Ingelheim, Contrafect, GlaxoSmithKline, Pfizer, Pulmonx, Roche, Spiration, Sunovion, Teva, Pearl Therapeutics, Merck, and Bonti outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. We express appreciation for the efforts of our field staff and thank all the participants of our studies for their contributions. The Pulmonary Risk in South America Study was sponsored and funded by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH) in the United States (contract no. 268200900029C). The CRONICAS study was supported by the NHLBI (contract no. HHSN268200900033C). The Lung Function in Nakaseke and Kampala study was supported in part by the Fogarty International Center (grant no. 5R25TW009340) and by a COPD Discovery Award from Johns Hopkins University. W.C. is supported in part by the NIH (grant no. UM1HL134590). T.S. was supported by a National Research Service Award through the National Institute of Environmental Health Sciences of the NIH (grant no. 1F32ES028577). A.R. was supported by the NIH Office of the Director, Fogarty International Center, and the NHLBI through the International Clinical Research Fellows Program at Vanderbilt University (grant no. R24 TW007988) and the American Relief and Recovery Act. Disclosure of potential conflict of interest: R. A. Wise reports grants and/or personal fees from AstraZeneca/Medimmune, Boehringer Ingelheim, Contrafect, GlaxoSmithKline, Pfizer, Pulmonx, Roche, Spiration, Sunovion, Teva, Pearl Therapeutics, Merck, and Bonti outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
FundersFunding numbers
American Relief and Recovery Act
-
American Relief and Recovery Act.Disclosure
-
NIH Office of the Director , Fogarty International Center
-
NIH Office of the Director , Fogarty International Center
-
NIH
268200900029C
NHLBI
HHSN268200900033C
OD
-
FIC
R25TW009340
NIEHS
1F32ES028577
BI
-
Pfizer
-
AstraZeneca
-
GSK
-
Merck
-
Roche
-
Teva Pharmaceutical Industries
-
VU
R24 TW007988
JHU
UM1HL134590
Boehringer Ingelheim
-
Sunovion
-
Pearl Therapeutics
-
MedImmune
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Social media
4
Mentions
1
Citations
43
Captures
96